Prasad, V. K., Grimley, M., Papanicolaou, G., Yu, L. C., Florescu, D. F., Brundage, T. M., … Kurtzberg, J. (2014). Brincidofovir (CMX001) Is Well Tolerated in Highly Immunocompromised Pediatric Patients. In Biology of Blood and Marrow Transplantation (Vol. 20, pp. S93–S93). Elsevier BV. https://doi.org/10.1016/j.bbmt.2013.12.121

Prasad, Vinod K., Michael Grimley, Genovefa Papanicolaou, Lolie C. Yu, Diana F. Florescu, Thomas M. Brundage, Herve Mommeja-Marin, and Joanne Kurtzberg. “Brincidofovir (CMX001) Is Well Tolerated in Highly Immunocompromised Pediatric Patients.” In Biology of Blood and Marrow Transplantation, 20:S93–S93. Elsevier BV, 2014. https://doi.org/10.1016/j.bbmt.2013.12.121.

Prasad VK, Grimley M, Papanicolaou G, Yu LC, Florescu DF, Brundage TM, et al. Brincidofovir (CMX001) Is Well Tolerated in Highly Immunocompromised Pediatric Patients. In: Biology of Blood and Marrow Transplantation. Elsevier BV; 2014. p. S93–S93.

Prasad, Vinod K., et al. “Brincidofovir (CMX001) Is Well Tolerated in Highly Immunocompromised Pediatric Patients.” Biology of Blood and Marrow Transplantation, vol. 20, no. 2, Elsevier BV, 2014, pp. S93–S93. Crossref, doi:10.1016/j.bbmt.2013.12.121.

Prasad VK, Grimley M, Papanicolaou G, Yu LC, Florescu DF, Brundage TM, Mommeja-Marin H, Kurtzberg J. Brincidofovir (CMX001) Is Well Tolerated in Highly Immunocompromised Pediatric Patients. Biology of Blood and Marrow Transplantation. Elsevier BV; 2014. p. S93–S93.